| Year |
Citation |
Score |
| 2014 |
Dixon C, Olshefski D, Jain V, Decusatis C, Felter W, Carter J, Banikazemi M, Mann V, Tracey JM, Recio R. Software defined networking to support the software defined environment Ibm Journal of Research and Development. 58. DOI: 10.1147/Jrd.2014.2300365 |
0.407 |
|
| 2013 |
Banikazemi M, Olshefski D, Shaikh A, Tracey J, Wang G. Meridian: An SDN platform for cloud network services Ieee Communications Magazine. 51: 120-127. DOI: 10.1109/Mcom.2013.6461196 |
0.381 |
|
| 2009 |
Silva M, Banikazemi M, Butrico M, Daly D, Guthridge S, Moreira JE, Ruggiero WV. Scalable data center provisioning and control Ibm Journal of Research and Development. 53. DOI: 10.1147/Jrd.2009.5429064 |
0.393 |
|
| 2008 |
Banikazemi M, Hafner J, Belluomini W, Rao KK, Poff D, Abali B. Flipstone: Managing storage with fail-in-place and deferred maintenance service models Operating Systems Review (Acm). 42: 54-62. DOI: 10.1145/1341312.1341323 |
0.32 |
|
| 2008 |
Banikazemi M, Poff D, Abali B. PAM: a novel performance/power aware meta-scheduler for multi-core systems 2008 Sc - International Conference For High Performance Computing, Networking, Storage and Analysis, Sc 2008. DOI: 10.1109/SC.2008.5222643 |
0.344 |
|
| 2001 |
Banikazemi M, Liu J, Panda DK, Sadayappan P. Implementing TreadMarks over Virtual Interface Architecture on Myrinet and gigabit Ethernet: Challenges, design experience, and performance evaluation Proceedings of the International Conference On Parallel Processing. 2001: 167-174. DOI: 10.1109/ICPP.2001.952060 |
0.478 |
|
| 2001 |
Banikazemi M, Govindaraju RK, Blackmore R, Panda DK. MPI-LAPI: An efficient implementation of MPI for IBM RS/6000 SP systems Ieee Transactions On Parallel and Distributed Systems. 12: 1081-1093. DOI: 10.1109/71.963419 |
0.549 |
|
| 2001 |
Abali B, Stunkel CB, Herring J, Banikazemi M, Panda DK, Aykanat C, Aydogan Y. Adaptive routing on the new switch chip for IBM SP systems Journal of Parallel and Distributed Computing. 61: 1148-1179. DOI: 10.1006/Jpdc.2001.1747 |
0.514 |
|
| 2001 |
Banikazemi M, Abali B, Herger L, Panda DK. Design alternatives for virtual interface architecture and an implementation on IBM netfinity NT cluster Journal of Parallel and Distributed Computing. 61: 1512-1545. DOI: 10.1006/Jpdc.2001.1745 |
0.584 |
|
| 2000 |
Banikazemi M, Panda DK. Can scatter communication take advantage of multidestination message passing? Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 1970: 204-211. |
0.444 |
|
| 2000 |
Banikazemi M, Abali B, Panda DK. Comparison and evaluation of design choices for implementing the virtual interface architecture (VIA) Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 1797: 145-161. |
0.572 |
|
| 1996 |
Basak D, Panda DK, Banikazemi M. Benefits of processor clustering in designing large parallel systems: when and how? Ieee Symposium On Parallel and Distributed Processing - Proceedings. 286-290. |
0.377 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2013 |
Jose J, Banikazemi M, Belluomini W, Murthy C, Panda DK. MetaData persistence using storage class memory: Experiences with flash-backed DRAM Proceedings - 1st Workshop On Interactions of Nvm/Flash With Operating Systems and Workloads, Inflow 2013; Co-Located With: Sosp 2013 - 24th Acm Symposium On Operating Systems Principles. DOI: 10.1145/2527792.2527800 |
0.29 |
|
| 2012 |
Banikazemi M, Abali B. Eucalyptus: Support for effective use of persistent memory Proceedings of the 2012 Ieee 26th International Parallel and Distributed Processing Symposium Workshops, Ipdpsw 2012. 1152-1159. DOI: 10.1109/IPDPSW.2012.138 |
0.253 |
|
| 2005 |
Banikazemi M, Poff D, Abali B. Storage-based intrusion detection for Storage Area Networks (SANs) Proceedings - Twenty -Second Ieee/Thirteenth Nasa Goddard Conference On Mass Storage Systems and Technologies. 118-127. DOI: 10.1109/MSST.2005.33 |
0.225 |
|
| 2005 |
Banikazemi M, Poff D, Abali B. Storage-based file system integrity checker Storagess'05 - Proceedings of the 2005 Acm Workshop On Storage Security and Survivability. 57-63. DOI: 10.1145/1103780.1103789 |
0.221 |
|
| 2008 |
Shi L, Banikazemi M, Wang QB. Iceberg: An image streamer for space and time efficient provisioning of virtual machines Proceedings of the International Conference On Parallel Processing Workshops. 31-38. DOI: 10.1109/ICPP-W.2008.13 |
0.181 |
|
| 2001 |
Abali B, Banikazemi M, Shen X, Franke H, Poff DE, Smith TB. Hardware compressed main memory: Operating system support and performance evaluation Ieee Transactions On Computers. 50: 1219-1233. DOI: 10.1109/12.966496 |
0.144 |
|
| 2011 |
Bhattacharjee B, Ross KA, Lang C, Mihaila GA, Banikazemi M. Enhancing recovery using an SSD buffer pool extension 7th International Workshop On Data Management On New Hardware, Damon 2011 - in Conjunction With Acm Sigmod/Pods Conference. 10-16. DOI: 10.1145/1995441.1995443 |
0.113 |
|
| 2006 |
Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement Genetics in Medicine. 8: 539-548. PMID 16980809 DOI: 10.1097/01.gim.0000237866.70357.c6 |
0.098 |
|
| 2010 |
Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, Puga AC, Bonate PL, Peterschmitt MJ. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 116: 893-9. PMID 20439622 DOI: 10.1182/blood-2010-03-273151 |
0.068 |
|
| 1999 |
Banikazemi M, Diaz GA, Vossough P, Jalali M, Gelb BD. Refinement of the locus for thiamine-responsive megaloblastic anemia syndrome Journal of Investigative Medicine. 47. |
0.068 |
|
| 2001 |
Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. American Journal of Human Genetics. 68: 711-22. PMID 11179018 DOI: 10.1086/318809 |
0.063 |
|
| 2010 |
Banikazemi M. Fabry disease in pediatric patients Fabry Disease. 353-364. DOI: 10.1007/978-90-481-9033-1_22 |
0.06 |
|
| 2008 |
Cousins A, Lee P, Rorman D, Raas-Rothschild A, Banikazemi M, Waldek S, Thompson L. Home-based infusion therapy for patients with Fabry disease British Journal of Nursing (Mark Allen Publishing). 17: 653-657. PMID 18563007 |
0.059 |
|
| 2006 |
Desnick RJ, Banikazemi M. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy. NÉPhrologie & théRapeutique. 2: S172-85. PMID 17373219 |
0.055 |
|
| 1994 |
Gindilis V, Banikazemi M, Vyasankin A, Verlinsky O, Matveyev I, Verlinsky Y. Review: Borders, patterns, and distinctive families of homeodomains Journal of Assisted Reproduction and Genetics. 11: 244-269. PMID 7711388 DOI: 10.1007/BF02214344 |
0.046 |
|
| 2004 |
Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease American Journal of Human Genetics. 75: 65-74. PMID 15154115 DOI: 10.1086/422366 |
0.046 |
|
| 1999 |
Diaz GA, Banikazemi M, Oishi K, Desnick RJ, Gelb BD. Mutations in a new gene encoding a thiamine transporter cause thiamine- responsive megaloblastic anaemia syndrome Nature Genetics. 22: 309-312. PMID 10391223 DOI: 10.1038/10385 |
0.046 |
|
| 2009 |
Banikazemi M. LZB: Data compression with bounded references Proceedings - 2009 Data Compression Conference, Dcc 2009. 436. DOI: 10.1109/DCC.2009.70 |
0.045 |
|
| 1999 |
Banikazemi M, Diaz GA, Vossough P, Jalali M, Desnick RJ, Gelb BD. Localization of the thiamine-responsive megaloblastic anemia syndrome locus to a 1.4-cM region of 1q23 Molecular Genetics and Metabolism. 66: 193-198. PMID 10066388 DOI: 10.1006/Mgme.1998.2799 |
0.041 |
|
| 2010 |
Watt T, Burlina AP, Cazzorla C, Schönfeld D, Banikazemi M, Hopkin RJ, Martins AM, Sims K, Beitner-Johnson D, O'Brien F, Feldt-Rasmussen U. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry Genetics in Medicine. 12: 703-712. PMID 20885332 DOI: 10.1097/GIM.0b013e3181f13a4a |
0.039 |
|
| 2009 |
Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry Genetics in Medicine. 11: 790-796. PMID 19745746 DOI: 10.1097/GIM.0b013e3181bb05bb |
0.039 |
|
| 2008 |
Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Molecular Genetics and Metabolism. 93: 112-28. PMID 18037317 DOI: 10.1016/j.ymgme.2007.09.013 |
0.039 |
|
| 2007 |
Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. Journal of the American Society of Nephrology : Jasn. 18: 1547-57. PMID 17409312 DOI: 10.1681/Asn.2006080816 |
0.038 |
|
| 2009 |
Sims K, Politei J, Banikazemi M, Lee P. Stroke in fabry disease frequently occurs before diagnosis and in the absence of other clinical events: Natural history data from the fabry registry Stroke. 40: 788-794. PMID 19150871 DOI: 10.1161/STROKEAHA.108.526293 |
0.032 |
|
| 2007 |
Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. Journal of Inherited Metabolic Disease. 30: 184-92. PMID 17347915 DOI: 10.1007/s10545-007-0521-2 |
0.028 |
|
| 2006 |
Banikazemi M, Desnick RJ. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis? Nature Clinical Practice. Nephrology. 2: 72-3. PMID 16932395 DOI: 10.1038/Ncpneph0100 |
0.027 |
|
| 2005 |
Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Molecular Genetics and Metabolism. 85: 255-9. PMID 15939645 DOI: 10.1016/J.Ymgme.2005.04.009 |
0.027 |
|
| 2006 |
Nance CS, Klein CJ, Banikazemi M, Dikman SH, Phelps RG, McArthur JC, Rodriguez M, Desnick RJ. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Archives of Neurology. 63: 453-7. PMID 16533976 DOI: 10.1001/Archneur.63.3.453 |
0.026 |
|
| 2015 |
Jones SA, Valayannopoulos V, Schneider E, Eckert S, Banikazemi M, Bialer M, Cederbaum S, Chan A, Dhawan A, Di Rocco M, Domm J, Enns GM, Finegold D, Gargus JJ, Guardamagna O, et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 26312827 DOI: 10.1038/gim.2015.108 |
0.023 |
|
| 2002 |
Desnick RJ, Banikazemi M, Wasserstein M. Enzyme replacement therapy for fabry disease, an inherited nephropathy Clinical Nephrology. 57: 1-8. PMID 11837797 DOI: 10.5414/Cnp57001 |
0.023 |
|
| 2010 |
Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M, Packman S, Sims K, Solomon SD. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. European Heart Journal. 31: 1088-97. PMID 20061327 DOI: 10.1093/eurheartj/ehp588 |
0.022 |
|
| 2004 |
Glass RB, Astrin KH, Norton KI, Parsons R, Eng CM, Banikazemi M, Desnick RJ. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. Journal of Computer Assisted Tomography. 28: 158-68. PMID 15091117 DOI: 10.1097/00004728-200403000-00002 |
0.018 |
|
| 2007 |
Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Annals of Internal Medicine. 146: 77-86. PMID 17179052 DOI: 10.7326/0003-4819-146-2-200701160-00148 |
0.013 |
|
| 2008 |
Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatric Research. 64: 550-5. PMID 18596579 DOI: 10.1203/Pdr.0B013E318183F132 |
0.013 |
|
| 2009 |
Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 24: 2102-11. PMID 19218538 DOI: 10.1093/Ndt/Gfp031 |
0.01 |
|
| 2008 |
Weinreb NJ, Andersson HC, Banikazemi M, Barranger J, Beutler E, Charrow J, Grabowski GA, Hollak CE, Kaplan P, Mankin H, Mistry PK, Rosenbloom BE, Vom Dahl S, Zimran A. Prevalence of type 1 Gaucher disease in the United States. Archives of Internal Medicine. 168: 326-7; author reply . PMID 18268176 DOI: 10.1001/Archinternmed.2007.128 |
0.01 |
|
| 2001 |
Desnick RJ, Wasserstein MP, Banikazemi M. Fabry disease (α-Galactosidase a deficiency): Renal Involvement and enzyme replacement therapy Contributions to Nephrology. 136: 174-192. PMID 11688379 DOI: 10.1159/000060184 |
0.01 |
|
| Hide low-probability matches. |